Cette ETUDE DANO-NORVEGIENNE sur ASTRAZENECA

https://www.fhi.no/en/news/2021/norwegian-danish-study-of-rare-side-effects-in-connection-with-astrazeneca-/
The results show that there were increased rates of venous blood clots in the brain (cerebral venous thrombosis) in the first 28 days after vaccination. The researchers found that one additional case occurred for every 40,000 vaccinated. The risk of venous thrombosis (blood clots) in general was also increased by about one additional case for every 9,000 vaccinated. There was no increase in blood clots in the arteries or in the incidence of heart attacks or strokes. The incidence of haemorrhages and low platelet counts was also slightly increased. Although the risk of side effects is increased, the number of events found in the registries is low. The risk for each individual person who has been vaccinated is therefore still considered to be low.

“Norway and Denmark have good health registries that are of high quality and updated. We are therefore in a privileged position of having continuous access to current, reliable and privacy-protected knowledge about the effect and side effects after vaccination. Such studies are important to confirm or disprove suspected adverse reaction signals from spontaneous adverse event reports. Reliable data about the background occurrence of the relevant conditions are important for putting the findings in context,” explains Gulseth.

je comprends pas cette langue

tu as deux secondes pour reposter en Français ou mange ta ddb

On 11 March 2021, the Norwegian Institute of Public Health decided to temporarily pause vaccination with the AstraZeneca vaccine in Norway. The decision was made after reports of severe cases internationally, and a death in Denmark following vaccination. During the pause, there were also reports of similar cases and four deaths in Norway.

Cerebral venous thrombosis is a prominent feature of the new syndrome, known as 'Vaccine-induced Immune Thrombotic Thrombocytopenia' (VITT). This syndrome includes other severe side effects, such as large blood clots in veins from the gastrointestinal tract, liver and spleen.

In this study, both thrombosis (blood clots) and thrombocytopenia (low platelet count) were diagnoses that were more frequently found among vaccinated people, but this study has not studied VITT directly.

Following an overall assessment, the Norwegian Institute of Public Health has recommended not to use the AstraZeneca vaccine in the Norwegian Coronavirus Immunisation Programme. The Government will make the final decision on further use. Coronavirus vaccination has continued since March 11 using COVID-19 vaccines from BioNTech / Pfizer and Moderna.

Le 09 mai 2021 à 07:49:21 :
je comprends pas cette langue

tu as deux secondes pour reposter en Français ou mange ta ddb

Tu as deux secondes pour ouvrir deepl

Oui c'est criminel ce qu'il se passe

Etude anglaise : https://time.com/5953653/astrazeneca-vaccine-blood-clots-studies/
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot.

In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can block blood flow in veins and arteries. The researchers are referring to the condition as vaccine-induced immune thrombotic thrombocytopenia.

Les résultats montrent qu'il y a eu une augmentation des taux de caillots sanguins veineux dans le cerveau (thrombose veineuse cérébrale) dans les 28 premiers jours après la vaccination. Les chercheurs ont constaté qu'un cas supplémentaire s'est produit pour 40 000 vaccinés. Le risque de thrombose veineuse (caillots sanguins) en général a également augmenté d'environ un cas supplémentaire pour 9 000 vaccinés. Il n'y a pas eu d'augmentation des caillots sanguins dans les artères ou de l'incidence des crises cardiaques ou des accidents vasculaires cérébraux. L'incidence des hémorragies et des faibles taux de plaquettes a également légèrement augmenté. Bien que le risque d'effets secondaires soit accru, le nombre d'événements relevés dans les registres est faible. Le risque pour chaque personne qui a été vaccinée est donc toujours considéré comme faible.

"La Norvège et le Danemark disposent de bons registres de santé, de grande qualité et mis à jour. Nous sommes donc dans une position privilégiée pour avoir un accès continu à des connaissances actuelles, fiables et protégées par la confidentialité sur l'effet et les effets secondaires de la vaccination. Ces études sont importantes pour confirmer ou infirmer les signaux d'effets indésirables suspectés à partir des déclarations spontanées d'effets indésirables. Des données fiables sur l'occurrence de fond des conditions pertinentes sont importantes pour replacer les résultats dans leur contexte", explique Gulseth.

Traduit avec www.DeepL.com/Translator (version gratuite)

While the AstraZeneca vaccine is not yet authorized in the U.S., about 25 million people around the world have received it, and in March, after dozens of reports of blood clots occurring mainly in younger people who received the shot, and about 18 deaths, many countries temporarily halted vaccination. After reviewing the side effect, the European Medicines Agency (EMA) in April acknowledged the clot risk but concluded that the benefits of vaccination in protecting against COVID-19 outweighed the small risk posed by clotting. The agency recommended, however, that people under age 30 years be provided other vaccines if they were available.

These two NEJM reports will reignite questions about the safety of the vaccine, and potentially lead to new policies or even stricter monitoring of people who receive it. “The important thing is that the link to this peculiar problem of post-vaccination thrombosis which was mysterious—we now have an explanation for it,” says Dr. Theodore Warkentin, professor of pathology and molecular medicine at McMaster University and a co-author of one of the papers.

The AstraZeneca vaccine relies on a modified adenovirus that causes cold-like symptoms in chimpanzees; the chimp virus serves as a vehicle for delivering genes coding for the COVID-19 virus’ spike protein. Whether the clotting side effect, and the platelet-involved mechanism described in the two papers, is related to this vector platform isn’t clear. But it doesn’t bode well for the vector-based technology, which is only approved for use in a rabies vaccine for animals, and not to prevent any diseases in humans (other than COVID-19, of course). “These results cast a shadow on this vaccine and now other vaccines—the Russian vaccine, and Johnson & Johnson—relying on this technology,” says one vaccine expert who did not wish to be identified. “Now all of these will be looked at with higher scrutiny, and they should be.” On April 9, the EMA announced it is currently reviewing Johnson & Johnson-Janssen vaccine after four reports of clots in people vaccinated with the shot were reported, one of which was fatal.

But that roadmap won’t likely clarify why these people are developing the clots in reaction to the vaccine in the first place. “What is it? Is it something unique to the adenovirus vector, or something unique to the amount of adenovirus given?” says the vaccine expert.

Holme, a co-author of the Norwegian study, says that the cases of clotting among vaccinated people is rare, but worrisome. “This devastating adverse event occurs very, very seldomly,” he says. “But for me, it’s tough to see healthy people in their 30s and 40s dying [after receiving] the vaccine when they probably would have been fine with a COVID-19 infection.”

It’s a different scenario for the rest of the world, however. The vaccine has been authorized by the World Health Organization and the European Union, and public health leaders were looking to the AstraZeneca vaccine to protect much of the world’s population, since the shot is less expensive and doesn’t require storage under freezer temperatures as the vaccines from Pfizer-BioNTech and Moderna, the currently most widely available shots, do. But if the shot requires additional monitoring and resources to treat potential blood clot complications, that could negate the cost and storage advantages of the vaccine.

Le 09 mai 2021 à 07:49:21 Halukardu76 a écrit :
je comprends pas cette langue

tu as deux secondes pour reposter en Français ou mange ta ddb

j'avais même pas remarqué que c'était en anglais

on est en 2021, faut se mettre à jour et apprendre la langue d'internet

Le 09 mai 2021 à 07:49:21 :
je comprends pas cette langue

tu as deux secondes pour reposter en Français ou mange ta ddb

Putain mais les COTOREP qui comprennent pas l'anglais achetez vous un cerveau sérieux, sauf si t'as 11 ans alors dans ce cas go -15

up

up

Jusqu'à présent, plusieurs vaccins basés sur adénovirus sont dans des essais cliniques et précliniques. Les vaccins développés contre le VIH, le virus Ebola, le virus de la grippe, le falciparum de bacille de la tuberculose, et de Plasmodium sont actuel sous des tests cliniques humains. Il y a également des vaccins sous des essais précliniques développés contre le virus de la rage, le virus de dengue, et le coronavirus respiratoire de syndrome de Moyen-Orient. En attendant, des vaccins basés sur adénovirus pour les coronavirus 2 (SARS-CoV-2) de syndrôme respiratoire aigu sévère ont été autorisés de secours parmi la pandémie COVID-19.